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Background—The development of the Diagnostic and Statistical Manual of Mental Disorders
5th edition (DSM-5) and ICD-11 has led to reconsideration of diagnostic criteria for posttraumatic
stress disorder (PTSD). The World Mental Health (WMH) Surveys allow investigation of the
implications of the changing criteria compared to DSM-IV and ICD-10.
Methods—WMH Surveys in 13 countries asked respondents to enumerate all their lifetime
traumatic events (TEs) and randomly selected one TE per respondent for PTSD assessment.
DSMIV and ICD-10 PTSD were assessed for the 23,936 respondents who reported lifetime TEs in
these surveys with the fully structured Composite International Diagnostic Interview (CIDI).
DSM-5 and proposed ICD-11 criteria were approximated. Associations of the different criteria
sets with indicators of clinical severity (distress-impairment, suicidality, comorbid fear-distress
disorders, PTSD symptom duration) were examined to investigate the implications of using the
different systems.
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Results—A total of 5.6% of respondents met criteria for “broadly defined” PTSD (i.e., full
criteria in at least one diagnostic system), with prevalence ranging from 3.0% with DSM-5 to
4.4% with ICD-10. Only one-third of broadly defined cases met criteria in all four systems and
another one third in only one system (narrowly defined cases). Between-system differences in
indicators of clinical severity suggest that ICD-10 criteria are least strict and DSM-IV criteria
most strict. The more striking result, though, is that significantly elevated indicators of clinical
significance were found even for narrowly defined cases for each of the four diagnostic systems.
Conclusions—These results argue for a broad definition of PTSD defined by any one of the
different systems to capture all clinically significant cases of PTSD in future studies.
Keywords
Posttraumatic stress disorder; World Mental Health Surveys; epidemiology; nosology; DSM-IV;
DSM-5; ICD-10; ICD-11
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Diagnostic criteria for posttraumatic stress disorder (PTSD) have changed with each edition
of the Diagnostic and Statistical Manual of Mental Disorders (DSM), including the recent
release of DSM-5, reflecting in part debates about the distinctions between normal responses
to traumatic stressors versus maladaptive reactions[1] and the potential for inappropriate
medicalization of suffering.[2] The diagnostic criteria for PTSD have also varied across
editions of the International Classification of Diseases (ICD), with anticipated tightening of
criteria in the forthcoming 11th edition in order to emphasize the importance of avoiding
overdiagnosis of PTSD.[3] These changes to the PTSD diagnosis, evident in DSM-5 and
anticipated in ICD-11, have reinvigorated debate about the appropriate criteria for PTSD and
the implications of differences in diagnostic criteria across each of the diagnostic
systems.[4–8]
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DSM-IV and ICD-10 criteria for PTSD differ in multiple ways (Appendix, Table A1). First,
DSM-IV defined the traumatic event (TE) as one that causes threat to the integrity of the
person or others (A1 criterion), with the reaction of the individual characterized by intense
fear, helplessness, or horror (A2 criterion),[9] whereas ICD-10 Diagnostic Criteria for
Research (ICD-10-DCR) refer to the importance of events that precipitate distress in almost
anyone.[10] Second, although DSM-IV criteria include both avoidance and numbing
symptoms, ICD-10-DCR includes only the presence of avoidance symptoms. Third, DSMIV requires the presence of clinically significant distress or impairment, whereas ICD-10DCR does not. Fourth, DSM-IV requires that symptoms continue for at least 1 month,
whereas ICD-10-DCR emphasizes that symptoms begin within 6 months of the event and
that some persist, but does not specify a minimum required duration.

NIH-PA Author Manuscript

Two important changes to the definition of a traumatic stressor and the associated symptoms
needed to qualify for a PTSD diagnosis have been made in DSM-5[11] (Appendix, Table
A1). First, based on evidence that the A2 criterion had insufficient clinical utility, the
requirement of a subjective response of fear, helplessness, or horror to the event was
eliminated.[4] By eliminating A2, DSM-5 expanded the context of PTSD from exclusively a
fear-based anxiety disorder to a disorder that also included anhedonic/dysphoric and
externalizing phenotypes. Second, based on factor analyses of PTSD symptoms,[4] the
number of clusters of PTSD symptoms required to qualify for a diagnosis was increased
from 3 to 4, with avoidance and numbing symptoms split into separate clusters and
expanded to represent avoidance and persistent negative alterations in cognitions and mood.
The expanded symptoms include persistent negative evaluation of self or others, elevated
self-blame, a negative emotional state, and reckless or self-destructive behavior.
Anticipated revisions to the PTSD diagnosis in ICD-11[3,12,13] emphasize that the construct
of PTSD should have both global applicability and clinical utility,[14] reflecting concerns
about the potential overuse of PTSD in disaster-exposed populations[15] (Appendix, Table
A1). In keeping with previous recommendations,[16,17] the ICD-11 workgroup has
recommended including three core symptom clusters (re-experiencing, avoidance of
traumatic reminders, and hyperarousal) and removing nonspecific symptoms that are also
found in other conditions (e.g., trouble concentrating, sleep problems). Re-experiencing the
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TE refers not only to remembering the event, but also to experiencing the event as occurring
again, as in nightmares and flashbacks. Duration of required symptoms and degree of
functional impairment are used to differentiate normal reactions to traumatic stressors from
PTSD, and PTSD is differentiated from complex PTSD that is also characterized by a range
of other disturbances.[12] By using a narrower and briefer ICD-11 set of symptoms, ICD-11
aims to better differentiate PTSD from often comorbid conditions.
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Several questions about these changes and differences deserve further consideration. First, is
the DSM-5 suggestion of four symptom clusters supported by investigation of symptom
structure in a cross-national sample? Second, what is the impact of changes in the diagnostic
criteria sets on PTSD prevalence cross-nationally? Third, to what extent do the diagnostic
criteria identify overlapping populations of individuals? Previous evidence suggests that
prevalence estimates of DSM-IV and ICD-10 PTSD are similar but that the systems identify
somewhat distinct sets of individuals, although this research is based only on data from one
country.[18] Fourth, do individuals diagnosed with PTSD using each of the diagnostic
criteria sets exhibit similar clinical characteristics, including distress, impairment,
suicidality, and comorbidity? Given that ICD-10 does not require distress and impairment
for diagnosis, it is likely that ICD-10 cases on average are associated with lower levels of
such outcomes. Again, prior comparison of DSMIV and ICD-10 PTSD has shown that
absence of the distress/impairment criterion results in higher PTSD prevalence in
ICD-10.[18] Fifth, as part of a broader concern with implications of differences among
systems, is PTSD differentially associated with sociodemographic factors, TE types, and
prior lifetime history of mental disorder across the systems?
Answering these questions is key to understanding the global impact of changes to the
diagnostic criteria sets for PTSD. The World Mental Health (WMH) Surveys, a dataset
comprising thousands of respondents from around the globe, and employing a diagnostic
instrument with both DSM and ICD criteria for PTSD, provides an important opportunity
for beginning to do so.

METHODS
SAMPLES
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Interviews were administered in 13 countries, including eight classified by the World
Bank[19] as high income (Belgium, Germany, Italy, Japan, Netherlands, New Zealand,
Spain, United States), four upper-middle income (São Paulo in Brazil, Bulgaria, Mexico,
Romania), and one lower-middle income (Colombia). Most surveys were based on
nationally representative household samples, the exceptions being surveys of all urbanized
areas in Colombia and Mexico and of specific Metropolitan areas in Brazil (São Paulo) and
a series of cities in Japan. Response rates ranged from 55.1% (Japan) to 87.7% (Colombia).
The weighted (by sample size) mean response rate across surveys was 70.3%. Interviews
were in two parts. Part I, administered to all respondents, assessed core DSM-IV mental
disorders (n = 67,652 respondents across all 13 surveys). Part II assessed additional
disorders and correlates. Questions about PTSD were included in Part II, which was
administered to 100% of Part I respondents who met lifetime criteria for any Part I disorder
and a probability subsample of other Part I respondents (n = 34,321 across all 13 surveys).
Depress Anxiety. Author manuscript; available in PMC 2014 October 28.
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Part II respondents were weighted by the inverse of their probability of selection from Part I
to adjust for differential probabilities of selection. Additional weights adjusted for
differential within and between household selection and deviations between the sample and
population demographic–geographic distributions. More details about WMH sample design
and weighting are presented elsewhere.[20]
MEASURES
Interview Procedures—Interviews were administered face-to-face in respondent homes
after obtaining informed consent using procedures approved by local Institutional Review
Boards. The interview schedule was developed in English and translated into other
languages using a standardized WHO translation, back-translation, and harmonization
protocol.[21] The full text of the interview schedule is available at
www.hcp.med.harvard.edu/wmh.
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TEs—The WMH interview assessed lifetime exposure to 29 TEs, including seven warrelated (e.g., combatant, civilian in a war zone), five types of physical assault (e.g., beaten
by a caregiver as a child, mugged), three types of sexual assault (e.g., stalked, attempted
rape, rape), six involving threats to physical integrity excluding violence (e.g., lifethreatening accidents, natural disasters), five involving threats to loved ones (e.g., lifethreatening illness/injury), and traumatic death of loved one. Two additional open-ended
questions asked about TEs not included on the list and TEs respondents did not wish to
describe concretely. Respondents were probed separately about number of lifetime
occurrences and age at first occurrence of each reported TE type. PTSD was assessed in
relation to a randomly selected lifetime TE to produce a population-level representative
sample of TEs.[22] This was done by numbering each occurrence of each reported TE for
each respondent, then selecting one numbered instance, and then weighting that report by
the probability of selection of that particular TE for that respondent. This approach produces
a weighted dataset representative of all lifetime TEs occurring to all respondents. Twentythree thousand nine hundred thirty-six Part II respondents (67.1%) reported one or more
TEs, with 24.6% of those with TEs reporting exactly one and the others reporting a mean of
6.0 (range 2–160; interquartile range 3–6), for approximately 114,000 TEs. Although PTSD
was assessed only for one TE per respondent, the sum of weights of these 23,936
respondents was equal to the total number of TEs rather than the number of respondents.
PTSD—Mental disorders were assessed with the Composite International Diagnostic
Interview (CIDI),[22] a fully structured interview administered by trained lay interviewers, to
assess DSM-IV and ICD-10 disorders. The CIDI assessment of PTSD began with questions
to operationalize the DSM-IV Criterion A2 requirement that the person’s response to the
focal TE involve intense fear, helplessness, or horror. However, rather than requiring
responses of this time, all respondents with qualifying TEs were additionally asked about
DSMIV Criterion B symptoms of persistent re-experiencing, Criterion C symptoms of
persistent avoidance, and Criterion D symptoms of persistent symptoms of increased
arousal. Respondents who reported any of these symptoms were then asked about the DSMIV Criterion E requirement that symptoms persist more than 1 month and the Criterion F
requirement that these symptoms cause clinically significant distress or impairment.
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As detailed elsewhere,[23] blinded clinical reappraisal interviews with the Structured Clinical
Interview for DSM-IV (SCID) were conducted in four WMH countries. CIDI–SCID
concordance for DSMIV PTSD was moderate[24] (κ = .49; area under the curve (AUC) = .
69). The two components of AUC, sensitivity and specificity, were 38.3 and 99.1,
respectively, resulting in a likelihood ratio positive (LR+) of 42.0, which is well above the
threshold of 10 typically used to consider screening scale diagnoses definitive.[25]
Consistent with the high LR+, the proportion of CIDI cases confirmed by the SCID was
86.1%, suggesting that the vast majority CIDI cases of DSM-IV PTSD would independently
be judged to have DSM-IV PTSD by trained clinicians.

NIH-PA Author Manuscript

ICD-10 criteria were also fully operationalized in the CIDI, as ICD-10 Criteria B–D are a
subset of the DSM-IV criteria. DSM-5 criteria (11) were approximated by fully
operationalizing DSM-5 Criteria B (one or more of five symptoms of intrusive recollection),
C (one or both of two symptoms of avoidance), F (duration of more than 1 month), and G
(clinically significant distress or impairment), and partially operationalizing Criteria D (two
or more of four symptoms of negative alterations in cognitions and mood, three of which
were not assessed in the CIDI) and E (two or more of five symptoms of marked alterations
in arousal and reactivity, one of which was not assessed in the CIDI). Proposed ICD-11
diagnostic guidelines (3) were approximated by operationalizing the requirements of (1)
avoidance of thoughts– memories of the TE or of activities–situations reminiscent of the TE,
(2) excessive hypervigilance or enhanced startle reactions, and (3) significant impairment in
functioning, while closely approximating the requirement of (4) re-experiencing the TE in
the form of either vivid intrusive memories, flashbacks, or nightmares accompanied by fear
or horror.
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Other Mental Disorders—In addition to PTSD, the CIDI assessed five DSM-IV fear
disorders (panic disorder without agoraphobia, specific phobia, social phobia, agoraphobia
without history of panic disorder, obsessive compulsive disorder), three distress disorders
(major depressive disorder/dysthymia, generalized anxiety disorder, bipolar disorders [I-II
and subthreshold BPD]), three disruptive behavior disorders (oppositional defiant disorder
[ODD], conduct disorder [CD], intermittent explosive disorder), and two substance disorders
(alcohol and drug abuse with or without dependence). Age-of-onset of each disorder was
assessed using special probing techniques shown experimentally to improve recall
accuracy.[26] DSM-IV organic exclusion rules and diagnostic hierarchy rules were used
(other than for ODD, which was defined with or without CD, and substance abuse, which
was defined with or without dependence). As detailed elsewhere,[23] generally good
concordance was found between these CIDI diagnoses and blinded clinical diagnoses based
on clinical reappraisal interviews with the SCID.[27]
Other Predictors—Differential predictors of the different types of PTSD were
investigated. The predictors included gender, age at TE exposure, TE type (war-related,
other interpersonal violence, intimate/sexual violence, accidents, death of loved one, other
network TEs, and other TEs), numbers of temporally prior lifetime fear/distress disorders
(anxiety and mood disorders), and number of temporally prior lifetime behavior/substance
disorders.
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Outcomes—The following four outcomes are considered here: severe distress or
impairment associated with symptoms of PTSD, as assessed by CIDI questions requiring
first lifetime onset of suicidal ideation in conjunction with the focal TE in the subsample of
respondents with no prior lifetime history of suicidality; and first lifetime onset of any fear
disorders or any distress disorder in the subsample of respondents with no prior lifetime
history of those disorders. Suicidality was assessed with the CIDI suicidal behavior
module.[22]

ANALYSIS METHODS
Multivariate additive associations among PTSD symptoms were examined with exploratory
factor analysis (EFA) of the tetrachoric correlation matrix between all logically possible
pairs of dichotomously scored symptoms. The parallel analysis simulation method[28] was
used to select the number of factors to retain in the analysis, whereas promax rotation was
used to improve our ability to interpret the solution. Prevalence estimates of PTSD based on
each of the four diagnostic systems, on any of the four systems (referred to below as broadly
defined PTSD), and on multisystem profiles were then estimated with cross-tabulations.
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Regression analysis was then used to examine the associations of PTSD according to the
different diagnostic systems with each of the four outcomes. As the cross-tabulations
showed that the numbers of cases in some of the 15 logically possible multivariate profiles
of diagnoses across the four systems (i.e., 24–1) were too small to allow completely
disaggregated comparisons, we made only three comparisons for each of the four diagnostic
systems for each outcome: (1) between narrow cases within the diagnostic system (i.e.,
cases that met criteria for PTSD according to the criteria of the system but not according to
the criteria of any of the other three systems) and broadly defined noncases (i.e., respondents
that did not meet criteria for PTSD according to the criteria of any of the four systems); (2)
between total cases within the diagnostic system (i.e., cases that met criteria for PTSD
according to the criteria of the system whether or not they also meet criteria in any of the
other three systems) and broadly defined non-cases; and (3) between other cases (i.e., cases
that did meet criteria for PTSD according to the criteria of the system but did meet criteria
for at least one of the other three systems) and broadly defined non-cases.
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The equations to predict comorbid fear and distress disorders predicted lifetime first onset of
each such disorder in the year of TE exposure in the subsample of respondents without a
prior lifetime history of the outcome disorder. These equations to predict comorbidity were
based on a combined person-disorder data array. For example, a separate sample of eligible
respondents was defined for each of the five fear disorders depending on prior lifetime
history of that disorder, these five datasets were then combined, and a single logistic
regression equation was estimated in this combined dataset (with four dummy control
variables to distinguish among the five disorders) to estimate a single set of predictor
coefficients constrained to be equal across all five outcomes.
We then used logistic regression to examine differences in the sociodemographic, traumarelated, and psychopathological predictors of PTSD in the four different types of PTSD.
This was done by estimating four logistic regression equations, one for PTSD diagnoses in
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each system, that used information about gender, age at TE exposure, type of TE (using the
seven-category classification scheme described above with traumatic death of a loved one
serving as the reference category), and prior (to the age of TE exposure) lifetime history of
fear/distress and behavior/substance disorders (dummy variables for exactly one and more
than one disorder of each type) to distinguish between total cases according to the focal
system and other cases. Logistic regression coefficients and their standard errors were
exponentiated and are reported here as odds ratios (ORs) with 95% confidence intervals
(CIs). Statistical significance was consistently evaluated using .05-level two-sided tests. The
design-based Taylor series method implemented in the SAS software system[29] was used to
adjust for the weighting and clustering of observations.

RESULTS
EFA
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EFA was carried out on the matrix of tetrachoric correlations among the 17 DSM-IV
Criterion B–D symptoms of PTSD assessed in the WMH surveys. Parallel analysis showed
that four meaningful factors exist in the data (Table 1). Promax rotation lead to a solution
that corresponded closely to the DSM-5 symptom dimensions of re-experiencing, avoidance,
numbing, and arousal.
PREVALENCE
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A total of 5.6% of respondents meet criteria for PTSD in at least one of the four systems
(Table 2). We refer to these cases below as having broadly defined PTSD. The system with
the highest prevalence (standard error in parentheses) is ICD-10 (4.4% [0.3], including
79.4% of all broadly defined cases), followed by DSM-IV and ICD-11 (3.3 [0.2] and 3.2%
[0.2], including 58.4 and 57.4%, respectively, of all broadly defined cases), and the lowest is
DSM-5 (3.0% [0.2], including 53.5% of all broadly defined cases; (Table 3). One-third of
broadly defined cases (1.8% of all respondents) meet criteria in all four systems, an
additional one-third of broadly defined cases in either three (0.9% of all respondents) or two
(an additional 0.9% of all respondents) systems, and the final one-third of broadly defined
cases (1.9% of all respondents) in only one of the four systems. The much higher prevalence
of cases based on ICD-10 than the other systems is reflected in the fact that narrow ICD-10
PTSD is the second most common profile (22.1% of all broadly defined cases), the most
common being cases meeting criteria in all four systems, while the other narrowly defined
types are quite uncommon (1.5–6.3% of all broadly defined cases).
VARIATION IN ADVERSE OUTCOMES ASSOCIATED WITH THE DIFFERENT TYPES OF
PTSD
The vast majority (95%) of the 44 ORs that compare outcomes among respondents with
PTSD to out comes among respondents classified as broadly defined noncases are greater
than 1.0 and statistically significant (89%; Table 4). The same is true of all four ORs
associated with narrowly defined DSM-IV PTSD, all four of those associated with narrowly
defined DSM-5 PTSD, three of the four ORs associated with narrowly defined ICD-10
PTSD, and one of the four ORs associated with narrowly defined ICD-11 PTSD. These
results suggest that each of the four diagnostic systems detects at least some clinically
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significant cases that are missed by all the other systems. Narrowly defined DSM-IV cases
tend to be more severe than DSM-IV cases that also meet criteria for PTSD in any of the
other systems. The opposite is true for narrowly defined ICD-10 and ICD-11 cases, both of
which have consistently lower severity scores than total cases. The number of narrowly
defined DSM-5 cases is so small that comparisons between narrowly defined and total
DSM-5 cases cannot be made. Total DSM-IV and DSM-5 cases are consistently more
severe than other cases, while total ICD-10 and ICD-11 cases are for the most part less
severe than other cases.
DIFFERENTIAL PREDICTORS

NIH-PA Author Manuscript

The associations of age of TE exposure and gender with PTSD risk do not vary significantly
across the four diagnostic systems (Table 5). However, there is some variation in the
differential risk of PTSD across TE types depending on the diagnostic system used to define
PTSD. The most important source of this variation is that interpersonal violence is
associated with significantly higher PTSD risk relative to traumatic death of a loved one
when PTSD is defined using ICD-11 criteria (which is true for 57.4% of respondents with
broadly defined PTSD) rather than criteria based on any of the other diagnostic systems
(which is true for the remaining 42.6% of respondents with broadly defined PTSD). There is
also evidence that traumatic death of a loved one is associated with significantly higher
PTSD risk relative to a number of other TEs when PTSD is defined using narrowly defined
DSM-IV criteria rather than other criteria. However, given that only 4.4% of respondents
with broadly defined PTSD have narrowly defined DSM-IV PTSD, these differences are not
as important as those associated with ICD-11 PTSD. The associations of prior lifetime
DSM-IV fear/distress and behavior/substance disorders with PTSD risk do not vary
significantly across the four diagnostic systems other than for a greater importance of having
exactly one prior externalizing disorder in the small proportion of cases where PTSD is
defined using narrowly defined DSM-IV criteria rather than other criteria. Finally, predictors
of broadly defined PTSD include female gender (OR = 1.8), sexual assault (OR = 2.6), and
prior history of fear/distress (OR = 2.0–4.3) or behavior/substance (OR = 2.0–4.3) disorders.

DISCUSSION
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This analysis has a number of limitations, the most important being that PTSD was assessed
using fully structured lay-administered interviews rather than semistructured clinical
interviews, that the interviews were based on retrospective reports about lifetime rather than
recent TEs, that DSM-5 criteria were incompletely operationalized (in particular the newly
added DSM-5 symptoms were not assessed), and that the proposed ICD-11 diagnostic
guidelines are not written as research criteria and needed to be approximated. As a
consequence, the results reported here are likely imprecise, and possibly biased (e.g., with
underestimation of DSM-5 PTSD prevalence). Nevertheless, the analysis is valuable insofar
as these are the first large-scale cross-national data comparing DSM-IV, DSM-5, ICD-10,
and ICD-11 PTSD.
Five findings are noteworthy. The first is that the EFA reported here mirrors the DSM-5
approach of distinguishing four PTSD symptom clusters.[11] Although a number of previous
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analyses have also yielded a four-factor solution,[4,30] there has been debate about whether
the fourth factor should be limited to numbing or should include nonspecific arousal
symptoms.[31,32] The current findings are the first based on a large cross-national sample
and support a model in which the factors are re-experiencing, avoidance, numbing, and
arousal. However, further work, for example, with confirma-tory factor analyses, is needed
to address fully ongoing debates in the literature about the structure of PTSD symptoms.[33]
Second, although 5.6% of respondents met criteria for “broadly defined” PTSD (in which
PTSD criteria for any diagnostic system are met), a similar proportion of these broadly
defined cases met criteria for DSM-5 (53.5 or 3% of total sample) and ICD-11 (57.4 or 3.2%
of total sample). These diagnostic systems are likely to have similar clinical utility in terms
of identifying similar proportions of the population. A larger proportion of respondents with
broadly defined PTSD met ICD-10 diagnostic criteria, consistent with the more stringent,
conservative approach to PTSD diagnosis taken by DSM-5 and ICD-11.
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Third, the different diagnostic systems detect populations of PTSD that show only partial
overlap. One-third of broadly defined cases (1.8% of all respondents) meet criteria in all
four systems, an additional one-third in either three (0.9% of all respondents) or two (an
additional 0.9% of all respondents) systems, and the final one-third (1.9% of all
respondents) in only one of the four systems. Narrowly defined ICD-10 PTSD comprises
22.1% of all broadly defined cases, but other narrowly defined types are quite uncommon
(1.5–6.3% of all broadly defined cases).
Fourth, while differences in associations with indicators of clinical severity are consistent
with ICD-10 criteria being least strict and DSM-IV criteria most strict (and as intended,
ICD-11 PTSD is associated with less comorbidity), the more striking result is that indicators
of clinical significance are found even for narrowly defined cases across all four diagnostic
systems. Thus, the use of any one diagnostic system will overlook many individuals who
suffer from clinically significant symptoms, including distress and impairment.
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Fifth, little evidence could be found for significant differences in sociodemographic, traumarelated, or prior lifetime psychopathological (including both fear/distress and behavioral/
substance disorders) predictors of PTSD across the different systems, indicating that there is
a similar underlying risk profile for PTSD irrespective of the definition. This general pattern,
and especially the finding that the associations of prior psychopathology with PTSD are
indistinguishable across the four diagnostic systems, adds support to the argument above
that all four definitions are providing information on unique clinically significant cases that
are omitted from the other systems.
These findings extend previous work comparing different diagnostic criteria sets for
PTSD,[18,34–37] and are consistent with the argument that refinements to DSMIV aimed at
removing symptoms that overlap with those of other mood and anxiety disorders, are not
associated with a major change in prevalence of PTSD, nor with evidence of a change in
disability, comorbidity, or structural validity.[38–41] Based on these findings, we suggest that
broadly defined PTSD may be a particularly useful additional construct in future
epidemiological studies of PTSD.
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APPENDIX
TABLE A1

PTSD criteria in DSM-IV, DSM-5, ICD-10, and ICD-11
Symptoms required
DSM-IV criteria
    A1. Exposure to actual or threatened death, serious injury, or a threat to physical integrity of
oneself or others
    A2. Response to the event involved fear, helplessness, or horror
    B. Persistent re-experiencing

One of five

    C. Persistent avoidance and numbing

Three of seven

    D. Persistent hyperarousal

Two of five

NIH-PA Author Manuscript

    E. Duration of at least 1 month
    F. Clinically significant distress/impairment
DSM-5 criteria
    A. Exposure to actual or threatened death, serious injury, or sexual violence
    B. Persistent re-experiencing

One of five

    C. Persistent avoidance

One of two

    D. Persistent numbing

Two of four

    E. Persistent hyperarousal

Two of five

    F. Duration of at least 1 month
    G. Clinically significant distress/impairment
ICD-10 criteria
    A. Exposure to a stressful event or situation of exceptionally threatening or catastrophic
nature likely to cause pervasive distress in almost anyone
    B. Persistent re-experiencing
    C. Avoidance

NIH-PA Author Manuscript

    D. Either (1) or (2) below:
    1. Inability to recall important aspects of the stressor
    2. Persistent hyperarousal
    E. Criteria B, C, and D must all be met within 6 months of the stressful event
ICD-11 criteria
    A. Exposure to a stressful event or situation of exceptionally threatening or horrific nature
likely to cause pervasive distress in almost anyone
    B. Persistent re-experiencing that involves not only remembering the TE, but also
experiencing it as occurring again
    C. Avoidance
    D. Persistent hyperarousal (i.e., heightened perception of current threat)
    E. Clinically significant functional impairment
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Rotated (promax) standardized regression coefficients based on EFA of CIDI PTSD symptom questions (n =
23,936)

a

I

II

III

IV

Repeated unwanted memories of random event

.84

Repeated unpleasant dreams about random event

.79

.11

.00

.03

.06

–.02

.05

Flashbacks of random event happening
Get very upset when reminded of random event

.84

.06

–.07

.05

.87

.00

.10

–.05

Have physical reactions when reminded of random event

.59

–.05

.16

.20

I. Re-experiencing

II. Avoidance
Try not to think about random event

.13

.82

–.05

.10

–.03

.75

.28

.05

–.01

.48

.46

–.10

Lose interest in things used to enjoy

.14

.09

.84

–.11

Feel emotionally distant/cut-off from people

.08

.14

.84

–.03

Trouble feeling love/happiness toward others

–.06

.12

.87

.08

Feel no reason to plan for the future

–.07

.09

.79

.11

Trouble falling asleep during random event

.32

–.12

.18

.50

More irritable than usual during random event

.09

–.17

.37

.55

More trouble concentrating during random event

.21

–.20

.50

.39

–.03

.22

–.14

.94

.08

.11

–.01

.83

Purposely stay away from things that remind of random event
III. Numbing
Unable to remember important parts of random event
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IV. Arousal

Much more alert/watchful with no real need
More easily startled by ordinary noises
a

Principal axis factor analysis of weighted (see the text for a discussion of weighting) tetrachoric correlation matrix of responses to dichotomous
symptom questions.
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Prevalence of PTSD according to the criteria of each and any of the four diagnostic systems (n = 23,936)
Total sample

a
Among respondents with broadly defined PTSD

Percentage

(SE)

Percentage

(SE)

DSM-IV

3.3

(0.2)

58.4

(2.5)

DSM-5

3.0

(0.2)

53.5

(2.5)

ICD-10

4.4

(0.3)

79.4

(2.2)

ICD-11

3.2

(0.2)

57.4

(2.7)

Any

5.6

(0.3)

100.0

-

n

23,936

1,581

a

Broadly defined PTSD = PTSD according to the criteria of any of the four systems.
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The cross-classification of PTSD prevalence across the four diagnostic systems (n = 23,936)
Total sample

Among respondents with broadly defined PTSD

Percentage

(SE)

Percentage

(SE)

1.8

(0.2)

33.1

(2.2)

    DSM-IV, DSM-5, ICD-10

0.4

(0.1)

7.7

(1.2)

    DSM-IV, DSM-5, ICD-11

0.3

(0.1)

5.8

(1.3)

    DSM-IV, ICD-10, ICD-11

0.1

(0.0)

2.6

(0.5)

    DSM-5, ICD-10, ICD-11

0.0

(0.0)

0.8

(0.5)

    Any three systems

0.9

(0.1)

16.8

(1.8)

    DSM-IV, DSM-5

0.1

(0.0)

0.9

(0.3)

    DSM-IV, ICD-10

0.2

(0.1)

2.8

(0.8)

    DSM-IV, ICD-11

0.1

(0.1)

1.4

(1.1)

    DSM-5, ICD-10

0.2

(0.1)

3.3

(1.0)

    DSM-5, ICD-11

0.0

(0.0)

0.5

(0.3)

    ICD-10, ICD-11

0.4

(0.1)

7.0

(1.2)

    Any two systems

0.9

(0.1)

15.8

(1.8)

    DSM-IV

0.2

(0.0)

4.4

(0.8)

    DSM-5

0.1

(0.0)

1.5

(0.7)

    ICD-10

1.2

(0.2)

22.1

(2.4)

    ICD-11

0.4

(0.1)

6.3

(1.2)

    Any one system

1.9

(0.2)

34.3

(2.4)

5.6

(0.3)

100.00

I. Meets criteria in all four systems
    DSM-IV, DSM-5, ICD-10,ICD-11
II. Meets criteria in three systems

III. Meets criteria in two systems
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IV. Meets criteria in one system

V. Meet criteria in any of the four systems
    Any
n

23,936
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a

2.2

    No PTSD

n

63.8

82.4

    All others

    Total

a

    Narrow

57.2

2.2

    No PTSD

IV.ICD-11

78.7

73.4

    All others

    Total

a

    Narrow

52.0

2.2

    No PTSD

III. ICD-10

59.4

87.5

    All others

    Total

a

ab
    Narrow ,
-

2.2

    No PTSD

II. DSM-5

62.0

83.3

90.9

    All others

    Total

a

    Narrow

a

I. DSM-IV

Percentage

(0.4)

(4.1)

(3.1)

(10.5)

(0.4)

(6.1)

(2.8)

(6.1)

(0.4)

(3.9)

(2.4)

-

(0.4)

(4.1)

(2.9)

(3.7)

(SE)

1.0
23,936

-

(61.5-141.6)

*

93.3

(211.3-566.7)

(32.9-241.4)

*

346.1

*

89.1

1.0

-

(135.9-550.2)

*

273.4

(114.2-236.3)

(28.1-95.7)

*

164.3

*

52.9

1.0

-

(56.7-118.8)

*

82.1

(289.9-837.5)

-

*

492.7

-

1.0

-

(63.4-145.5)

*

96.1

(202.0-512.4)

(177.2→999)

(95% CI)

*

321.7

*

497.7

OR

Severe distress or impairment

1.2

5.3

5.5

1.1

1.2

8.6

4.6

1.6

1.2

2.5

8.2

-

1.2

3.0

7.4

15.5

Percentage

(0.1)

(2.0)

(1.1)

(1.0)

(0.1)

(4.1)

(0.8)

(0.9)

(0.1)

(0.9)

(1.8)

-

(0.1)

(1.7)

(1.3)

(8.6)

(SE)

1.0

*
3.6

*
3.1

0.4

1.0

*

5.2

*

2.9

1.0

1.0

1.5

*

5.3

-

1.0

1.9

*

4.5

*

12.9

OR

Suicidality

c
(22,030)

-

(1.7-8.0)

(1.8-5.4)

(0.1-3.0)

-

(1.7-15.4)

(1.8-4.6)

(0.3-3.6)

-

(0.6-3.5)

(2.9-9.4)

-

-

(0.6-6.1)

(2.7-7.5)

(3.5-47.9)

(95% CI)

0.7

4.0

4.0

0.5

0.7

4.2

4.0

2.4

0.7

2.4

5.5

-

0.7

2.6

5.1

7.9

Percentage

*

1.0

*
5.8

*
5.3

0.5

1.0

*
5.7

*
5.4

*
3.6

1.0

*
3.2

7.8

-

1.0

*

3.7

*

6.8

*

11.1

OR

d
(79,83 6)

(0.1)

(0.8)

(0.6)

(0.2)

(0.1)

(1.2)

(0.5)

(0.9)

(0.1)

(0.5)

(0.8)

-

(0.1)

(0.7)

(0.7)

(2.2)

(SE)

Distress

-

(3.5-9.4)

(3.5-8.0)

(0.2-1.5)

-

(2.8-11.5)

(3.7-7.9)

(1.5-8.5)

-

(1.8-5.5)

(5.2-11.7)

-

-

(2.0-7.0)

(4.6-9.9)

(5.9-20.8)

(95% CI)

0.3

1.5

1.6

0.8

0.3

1.7

1.5

1.1

0.3

1.1

2.0

-

0.3

1.3

1.8

2.9

Percentage

Comorbid disorders

*

1.0

*
5.7

*
4.2

2.4

1.0

*
4.8

*
4.8

*
4.7

1.0

*
3.8

5.6

-

1.0

*
4.4

*
5.1

*
13.7

OR

e
(112,460)

(0.03)

(0.4)

(0.5)

(0.4)

(0.03)

(0.6)

(0.4)

(0.5)

(0.03)

(0.3)

(0.5)

-

(0.0)

(0.4)

(0.5)

(1.6)

(SE)

Fear

-

(3.2-10.0)

(2.0-8.9)

(0.7-8.0)

-

(2.4-9.5)

(2.6-8.9)

(1.8-12.2)

-

(1.9-7.4)

(3.0-10.4)

-

-

(2.2-8.6)

(2.6-9.9)

(4.3-44.0)

(95% CI)

Associations of PTSD classified by only one (“narrow” cases) versus more than one (“all other” cases) diagnostic system with indicators of clinical
significance among respondents exposed to a traumatic experience
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Respondents with narrow DSM-5 PTSD were excluded from analysis due to their small number.

Five fear disorders were included in the analysis (agoraphobia, panic disorder, separation anxiety disorder, social phobia, and specific phobia). A separate observational file was created for each of these
disorders, excluding respondents with a lifetime history of this disorder at an earlier age than when they experienced the focal TE. The four data files were then stacked and a single set of coefficients was
estimated for the pooled within-disorder odds of onset in the year of TE exposure. The sample size given here is for the stacked dataset. Disorder-specific samples ranged in size from 20,429 for specific
disorder to 23,629 for agoraphobic.

e

Four distress disorders were included in the analysis (major depressive disorder, bipolar disorder, generalized anxiety disorder, and obsessive-compulsive disorder). A separate observational file was
created for each of these disorders excluding respondents with a lifetime history of this disorder at an earlier age than when they experienced the focal TE. The four data files were then stacked and a single
set of coefficients was estimated for the pooled within-disorder odds of onset in the year of TE exposure. The sample size given here is for the stacked dataset. Disorder-specific samples ranged in size from
11,925 for obsessive-compulsive disorder (OCD) to 23,500 for bipolar disorder. The small sample size for OCD is due to the fact that OCD was assessed in only a subsample of cases in a subset of
countries.

d

c
Respondents with a history of suicidal ideation at an earlier age than when they experienced the focal TE were excluded.

b

Narrow cases are those that meet criteria for PTSD in the one diagnostic system represented in the subheading but in none of the other three systems. Total cases, in comparison, are all those who meet
criteria for PTSD in the diagnostic system represented in the subheading whether or not they also meet criteria in one or more of the other three systems. All others, finally, are all those who do not meet
criteria for PTSD in the diagnostic system represented in the subheading but do meet criteria in one or more of the three other systems. All three groups are contrasted with respondents who had a traumatic
experience but did not develop PTSD according to the criteria of any of the four systems.

a

Significantly different from respondents who did not meet criteria for PTSD in any of the four diagnostic systems at the .05 level, two-sided test.
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c

c

(0.4-0.8)

c

Accident
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c

Other

c

1
2.0

1.0

0

Fear/distress disorders

III. Lifetime prior history of mental disorders

χ62

1.0

Death
2.0

0.8

Network events

0.6

(1.5-2.7)

-

(1.4-3.0)

-

(0.5-1.2)

(1.9-3.8)

c

Intimate/sexual violence
2.6

(0.6-1.4)

0.9

(0.3-1.4)

(1.3-2.4)

Other interpersonal violence

88.1

15.4

0.1

(0.9-1.1)

(95% CI)

0.7

c

1.8

1.0

OR

War events

II. Trauma type

χ12

    Male

    Female

Sex

χ12

Age in decades

Age of traumatic exposure

I. Sociodemographic

Broadly defined PTSD
versus noncases

0.7

1.0

0.1

c

1.0

0.5

c

0.0

c

0.0

c

(0.3-1.8)

-

(0.0-0.4)

-

(0.2-1.5)

(0.0-0.2)

(0.0-0.2)

(0.0-0.4)

0.1

c

-

(0.7-4.1)

(0.0-0.0)

913.3

1.2

1.5

(0.7-1.1)

(95% CI)

c

0.0

1.0

1.7

0.9

OR

a
Narrow DSM-IV versus Others

1.3

1.0

0.9

1.0

(0.8-2.2)

-

(0.4-2.0)

-

(0.3-1.0)
0.5

c

(0.6-2.5)

(0.4-1.7)

(0.1-1.2)

-

(0.6-1.5)

(0.4-1.6)

9.9

0.0

2.2

(0.7-1.0)

(95% CI)

0.8

1.3

0.8

0.4

1.0

0.9

0.9

OR

b
Total DSM-5 versus others

1.2

1.0

1.5

1.0

1.5

1.7

0.4

0.9

1.3

1.0

0.8

1.2

OR

9.0

0.7

3.5

(0.6-2.2)

-

(0.5-4.6)

-

(0.7-3.4)

(0.4-6.4)

(0.2-1.1)

(0.4-2.4)

(0.3-6.3)

-

(0.4-1.5)

(1.0-1.5)

(95% CI)

a
Narrow ICD-10 versus
others

Among respondents with broadly defined PTSD

Sociodemographic and trauma-related predictors of broadly defined PTSD and PTSD based on each of the diagnostic systems

0.6

1.0

0.8

1.0

0.8

0.4

c
4.5

c
5.8

6.1

1.0

1.2

1.1

OR

(0.2-1.7)

-

(0.2-3.3)

-

(0.3-2.6)

(0.1-1.9)

(1.2-17.0)

(1.6-21.7)

(1.0-38.1)

-

(0.6-2.8)

16.3*

0.3

0.6

(0.8-1.5)

(95% CI)

a
Narrow ICD-11 versus
others
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(1.6-2.9)

23,936

n

1.1

5.5

c

1.0

1.6

OR

728

c

8.7

2.5

(0.2-6.1)

(1.7-17.4)

-

(0.5-5.2)

(95% CI)

1.6

1.1

1.0

1.2

OR

-

(0.7-3.7)

(0.6-2.1)

1,581

1.0

1.7

(0.8-1.9)

(95% CI)

1.4

0.8

1.0

1.0

OR

669

0.5

0.3

(0.3-6.3)

(0.3-1.9)

-

(0.5-2.2)

(95% CI)

a
Narrow ICD-10 versus
others

Narrow cases are those that meet criteria for PTSD in the one diagnostic system represented in the column heading but in none of the other three systems.

24.1

χ22

2.1

c

2+

(0.8-1.8)

1.2

1

-

1.0

c

c

83.7

0

Behavioral/substance disorders

χ22

(3.1-5.9)

c

4.3

(95% CI)

OR

b
Total DSM-5 versus others

c
0.2

0.6

1.0

1.1

OR

796

4.2

1.4

(0.0-1.0)

(0.2-2.3)

-

(0.4-3.2)

(95% CI)

a
Narrow ICD-11 versus
others

c
Significant difference between PTSD according to the diagnostic system indicated by the column heading and one or more of the other three diagnostic systems.

Total cases are all those who meet criteria for DSM-5 PTSD whether or not they also meet criteria in one or more of the other three systems. Total cases were used instead of narrow cases of DSM-5 PTSD
because of the rarity of narrow DSM-5 PTSD.

b

a
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2+

a
Narrow DSM-IV versus Others
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Broadly defined PTSD
versus noncases
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Among respondents with broadly defined PTSD
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